Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation

Journal of Clinical Oncology

Volumn 31, Issue 30, 2013, Pages 3782-3790

  Bari, Rafijul ^a   Rujkijyanont, Piya ^a   Sullivan, Erin ^a   Kang, Guolian ^a   Turner, Victoria ^a   Gan, Kwan ^a   Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; HLA C ANTIGEN; KIR2DL1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CHILD; CLINICAL OUTCOME; DISEASE COURSE; DONOR; FEMALE; GENE FREQUENCY; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PEDIATRIC SURGERY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; SURVIVAL RATE; ADOLESCENT; ALLELE; ALLOTRANSPLANTATION; ANALYSIS OF VARIANCE; DISEASE FREE SURVIVAL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ADOLESCENT; ALLELES; ANALYSIS OF VARIANCE; ARGININE; CHILD; CHILD, PRESCHOOL; CYSTEINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-C ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, KIR2DL1; TRANSPLANTATION, HOMOLOGOUS;

EID: 84891554529     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.4007     Document Type: Article

References (49)

1. Cooley S, Weisdorf DJ, Guethlein LA, et al: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116: 2411-2419, 2010
2. Chen DF, Prasad VK, Broadwater G, et al: Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. Bone Marrow Transplant 47:817-823, 2012
3. Venstrom JM, Pittari G, Gooley TA, et al: HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367:805-816, 2012
4. Malmberg KJ, Michaëlsson J, Parham P, et al: Killer cell immunoglobulin-like receptor workshop: Insights into evolution, genetics, function, and translation. Immunity 35:653-657, 2011
5. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100, 2002
6. Olson JA, Leveson-Gower DB, Gill S, et al: NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 115:4293-4301, 2010
7. Velardi A, Ruggeri L, Mancusi A: Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr Opin Hematol 19:319-323, 2012
8. Moretta L, Locatelli F, Pende D, et al: Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117:764-771, 2011
9. Leung W: Use of NK cell activity in cure by transplant. Br J Haematol 155:14-29, 2011
10. Hsu KC, Chida S, Geraghty DE, et al: The killer cell immunoglobulin-like receptor (KIR) genomic region: Gene-order, haplotypes and allelic polymorphism. Immunol Rev 190:40-52, 2002
11. Parham P, Moffett A: Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 13:133-144, 2013
12. Single RM, Martin MP, Gao X, et al: Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 39:1114-1119, 2007
13. Ruggeri L, Capanni M, Casucci M, et al: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339, 1999
14. Giebel S, Locatelli F, Wojnar J, et al: Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol 131:483-486, 2005
15. Hou LH, Steiner NK, Chen M, et al: KIR2DL1 allelic diversity: Four new alleles characterized in a bone marrow transplant population and three families. Tissue Antigens 69:250-254, 2007
16. Anfossi N, André P, Guia S, et al: Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331-342, 2006
17. Parham P: Taking license with natural killer cell maturation and repertoire development. Immunol Rev 214:155-160, 2006
18. Leung W, Iyengar R, Turner V, et al: Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172:644-650, 2004
19. Hsu KC, Keever-Taylor CA, Wilton A, et al: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105:4878-4884, 2005
20. Miller JS, Cooley S, Parham P, et al: Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109: 5058-5061, 2007
21. Yu J, Venstrom JM, Liu XR, et al: Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 113:3875-3884, 2009
22. Hsu KC, Gooley T, Malkki M, et al: KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 12:828-836, 2006
23. Scquizzato E, Zambello R, Teramo A, et al: KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation. Pediatr Transplant 15:198-204, 2011
24. Pando MJ, Gardiner CM, Gleimer M, et al: The protein made from a common allele of KIR3DL1 (3DL1∗004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 171:6640-6649, 2003
25. Steiner NK, Dakshanamurthy S, Vanden-Bussche CJ, et al: Extracellular domain alterations impact surface expression of stimulatory natural killer cell receptor KIR2DS5. Immunogenetics 60: 655-667, 2008
26. Goodridge JP, Lathbury LJ, Steiner NK, et al: Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells. Eur J Immunol 37:199-211, 2007
27. Yawata M, Yawata N, Draghi M, et al: Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 203:633-645, 2006
28. Bari R, Bell T, Leung WH, et al: Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 114:5182-5190, 2009
29. Bari R, Leung M, Turner VE, et al: Molecular determinant-based typing of KIR alleles and KIR ligands. Clin Immunol 138:274-281, 2011
30. Leung W, Campana D, Yang J, et al: High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 118:223-230, 2011
31. Leung WH, Turner V, Richardson SL, et al: Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 62:399-407, 2001
32. Vilches C, Castaño J, Gómez-Lozano N, et al: Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 70:415-422, 2007
33. Pende D, Marcenaro S, Falco M, et al: Antileukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113:3119-3129, 2009
34. Triplett B, Handgretinger R, Pui CH, et al: KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 107:1238-1239, 2006
35. Bernardo M, Zecca M, Giorgiani G, et al: Donor NK alloreactivity improves the outcome of children with haematological malignancies given transplantation of T-cell depleted peripheral blood haematopoietic stem cells from an HLA-disparate family donor. Bone Marrow Transplant 46:S16, 2011 (suppl; abstr 0172)
36. Kim S, Poursine-Laurent J, Truscott SM, et al: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:709-713, 2005
37. Yawata M, Yawata N, Draghi M, et al: MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112:2369-2380, 2008
38. Pyo CW, Guethlein LA, Vu Q, et al: Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS One 5:e15115, 2010
39. Parham P, Norman PJ, Abi-Rached L, et al: Human-specific evolution of killer cell immunoglobulinlike receptor recognition of major histocompatibility complex class I molecules. Philos Trans R Soc Lond B Biol Sci 367:800-811, 2012
40. Meenagh A, Gonzalez A, Sleator C, et al: Investigation of killer cell immunoglobulin-like receptor gene diversity, KIR2DL1 and KIR2DS1. Tissue Antigens 72:383-391, 2008
41. Chazara O, Xiong S, Moffett A: Maternal KIR and fetal HLA-C: A fine balance. J Leukoc Biol 90:703-716, 2011
42. Verheyden S, Schots R, Duquet W, et al: A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19:1446-1451, 2005
43. Cooley S, Trachtenberg E, Bergemann TL, et al: Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113:726-732, 2009
44. Kröger N, Binder T, Zabelina T, et al: Low number of donor activating killer immunoglobulinlike receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 82:1024-1030, 2006
45. Giebel S, Nowak I, Wojnar J, et al: Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donorhematopoietic cell transplantation. Transplant Proc 38:287-291, 2006
46. McQueen KL, Dorighi KM, Guethlein LA, et al: Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68:309-323, 2007
47. McErlean C, Gonzalez AA, Cunningham R, et al: Differential RNA expression of KIR alleles. Immunogenetics 62:431-440, 2010
48. Gagne K, Brizard G, Gueglio B, et al: Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 63:271-280, 2002
49. Leung W, Iyengar R, Triplett B, et al: Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174:6540-6545, 2005